Immunogenic oncolysis by tigilanol tiglate.
Oncoimmunology
; 13(1): 2360230, 2024.
Article
en En
| MEDLINE
| ID: mdl-38812571
ABSTRACT
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Oncoimmunology
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia